Biotech

All Articles

Merck stops period 3 TIGIT trial in bronchi cancer cells for impossibility

.Merck &amp Co.'s TIGIT course has actually experienced yet another setback. Months after shuttering...

After a hard year, Exscientia folds into Recursion

.After a year described by pipeline hairstyles, the variation of its own chief executive officer and...

Cullinan, after $25M offer, hands back bispecific to Port

.Cullinan Therapeutics was actually impressed sufficient with Harbour BioMed's bispecific immune act...

A nearer examine Ferocious Biotech's Fierce 15

.Within this full week's episode of "The Best Pipe," we are actually diving right into Intense Biote...

Lilly deals with stage 2 failure of tau-targeting med

.The confetti is actually still flying coming from Eli Lilly's party celebrating the approval of Alz...

Biogen CMO Maha Radhakrishnan signs up with Sofinnova-- Chutes &amp Ladders

.Invite to today's Chutes &amp Ladders, our roundup of considerable management hirings, firings and ...

Lykos are going to ask FDA to reevaluate its choice adhering to rejection of MDMA therapy for trauma

.Following a bad showing for Lykos Therapeutics' MDMA prospect for trauma at a recent FDA consultato...

AN 2 one-halfs census, stops stage 3 test after data let down

.AN2 Therapies is actually reconsidering its service in feedback to poor midphase data, vowing to la...

Merck pays for $700M for bispecific, spying autoimmune position as well as opportunity to challenge Amgen in cancer

.Merck &amp Co. is actually paying out $700 thousand in advance to test Amgen in a blood cancer mark...

Gilead pays out J&ampJ $320M to go out licensing deal for seladelpar

.Along With Gilead Sciences almost an FDA choice for its own liver health condition drug seladelpar,...